US Patent Issued to AKSTON BIOSCIENCES on Oct. 28 for "PD-L1 analog fusion proteins for antigen specific immunotherapy and methods of use" (Massachusetts Inventors)

ALEXANDRIA, Va., Oct. 28 -- United States Patent no. 12,454,565, issued on Oct. 28, was assigned to AKSTON BIOSCIENCES Corp. (Boston).

"PD-L1 analog fusion proteins for antigen specific immunotherapy and methods of use" was invented by Todd C. Zion (Salem, Mass.) and Thomas M. Lancaster (Wenham, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides recombinantly manufactured fusion proteins comprising a Programmed Death-Ligand 1 (PD-L1) protein fragment or an analog thereof linked to a canine Fc fragment. Embodiments include the administration of the fusion proteins to patients as a treatment for cancers, tumors or other diseases associated with expression of the PD-L1 protein ...